Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
1999-09-21
2002-03-12
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S738000
Reexamination Certificate
active
06355691
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to the field of treating carcinomas. More particularly, the invention relates to the regression and prevention of recurrence of transitional cell carcinoma in the bladder.
2. Prior Art
Conventionally, intravesical instillation of Bacille Calmette-Guerin (BCG) has been favored as the most effective therapy for superficial transitional cell carcinoma of the bladder. Such treatment with BCG is believed to create a local immunological reaction evidenced by cytokines and cytotoxic T cells in the urine of the patient following therapy. The cytokines indicate a coordinated antibody and T cell immune interaction and the cytotoxic T cells appear to lyse the carcinoma cells. While treatment of the patient with BCG is considered an effective treatment, drawbacks of BCG include liver and pulmonary dysfunction and disease. Because of the drawbacks many patients cannot tolerate such treatment. In addition, up to thirty percent of patients do not respond to the treatment.
Other contemporary treatments include keyhole limpet hemocyanin and mistletoe extract as a lectin. While both of these treatments show promise, they are experimental and unproven. Other immunotheraputic agents that have been investigated include interferons, and interleukin-2.
Thus, the medical art concerned with the treatment of transitional cell carcinoma of the bladder is in need of alternate treatment methods without the side effects noted above.
SUMMARY OF THE INVENTION
The above-identified drawbacks of the prior art are overcome or alleviated by the urushiol therapy of the invention.
Urushiol, the active immunogen in toxicodendron radicans (poison ivy) is employable through intravesical instillation to treat transitional cell carcinoma of the bladder. A water soluble analogue of urushiol is preferably instilled in the bladder and retained therein for a selected period of time and then drained through the same catheter by which it was instilled. The necessity and frequency of repeated treatments are then determined based upon local inflammatory response and the rate of success of the treatment. These are monitored preferably by interval cystoscopy. The urushiol composition instilled in the bladder creates significant local immune response in patients including those with immunosuppressed conditions.
The urushiol composition is preferably instilled in the bladder by a foley catheter with the composition being either a suspension or colloid or a solution.
REFERENCES:
Osol, Editor-in-Chief of Remington's Pharmaceutical Sciences, p. 772, Jun. 14, 1976.*
Byers, V. S. et al., “Modulation of Tumor Cell Membranes with Lipophilic Haptens: an Approach to Modifying Tumor Immunogenicity”, Abstract to ICN-UCLA symp. Mol. Cell. Biol. (1979), 16 (T B Lymphocytes: Recognition Funct.) , 603-622.*
ChunSoo et al., “In vitro cytotoxic activity of urushiol in the sap of Rhus verniciflua Stokes”, Abstract to Journal of Korean Forestry Society, vol. 87, No. 2, pp. 260-269, (1998).*
Hwang et al., “A Study on the Cytotoxic Activity of Extract of Urushiol of Lacquer Sap Against L-5178Y Cells”, Abstract to Korean J Biochem, 10(1), pp. 17-22, 1979.
LandOfFree
Urushiol therapy of transitional cell carcinoma of the bladder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urushiol therapy of transitional cell carcinoma of the bladder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urushiol therapy of transitional cell carcinoma of the bladder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2828500